1 – 10 of 11
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden : An observational cohort study
(
- Contribution to journal › Article
- 2023
-
Mark
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
2023) In Journal of Neurology, Neurosurgery and Psychiatry(
- Contribution to journal › Article
-
Mark
Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort
(
- Contribution to journal › Article
- 2022
-
Mark
COVID-19 clinical outcomes and DMT of MS patients and population-based controls
(
- Contribution to journal › Article
- 2020
-
Mark
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
(
- Contribution to journal › Article
-
Mark
Infection Risks among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
(
- Contribution to journal › Article
- 2014
-
Mark
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience
(
- Contribution to journal › Article
- 2011
-
Mark
Effect of Treatment with Natalizumab on Ability to Work in People with Multiple Sclerosis Productivity Gain Based on Direct Measurement of Work Capacity before and after 1 Year of Treatment
(
- Contribution to journal › Article
-
Mark
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
(
- Contribution to journal › Article
- 2010
-
Mark
Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease.
(
- Contribution to journal › Article